A Phase I Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Trial Profile

A Phase I Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Duvelisib (Primary) ; Bortezomib; Romidepsin
  • Indications T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Dec 2017 According to a Verastem media release, results were presented at the American Society of Hematology (ASH) 2017 Annual Meeting.
    • 11 Dec 2017 Results presented in a Verastem media release.
    • 07 Nov 2017 Data from this trial will be presented at the American Society of Hematology 2017 Annual Meeting (ASH 2017), according to a Verastem media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top